What is the typical dosing for 5-Amino-1MQ?

Research compound - not FDA approved. Common doses observed in research: 50-100 mg daily. Duration: 4-6 weeks (cycling recommended). Administration: Subcutaneous injection or oral.

Weight Loss

5-Amino-1MQ

Also known as: 5-amino-1-methylquinolinium, NNMT Inhibitor

Preclinical

Buy in shop

5-Amino-1MQ from $62/kit

3 verified vendors, ≥99% purity, COAs included.

Compare prices

Key Facts: 5-Amino-1MQ

Category: Weight Loss
FDA Status: Not FDA Approved
Clinical Status: Preclinical Research
Administration: Subcutaneous injection or oral
Typical Dose: 50-75 mg daily
Frequency: Once daily, morning
Duration: 4-6 weeks (cycling recommended)

Also Known As

5-amino-1-methylquinolinium, NNMT Inhibitor

Mechanism of Action

5-Amino-1MQ inhibits NNMT, an enzyme that regulates NAD+ and SAM (S-adenosyl methionine) levels. By blocking NNMT, it increases NAD+ availability, enhancing mitochondrial function, promoting fat oxidation, and supporting cellular energy metabolism. It does not affect appetite or food intake.

Research Summary

Mouse studies showed over 30% decrease in adipocyte size and 40% decrease in adipocyte volume. Treated mice had 30% lower total cholesterol. No significant impact on food intake or adverse effects observed. Human clinical data remains limited.

Trial Progress:Preclinical

Pre

III

FDA

Dosing Information

Animal Studies·Promising animal research, limited human data

Note: Animal study doses may not translate directly to humans.

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

50-75 mg daily

Range

50-100 mg daily

Frequency

Once daily, morning

Small molecule NNMT inhibitor. Cycle 4-6 weeks on, 2-4 weeks off. Weight-based: <150 lbs: 50-75mg, 150-200 lbs: 75mg, >200 lbs: 75-100mg.

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

Research compound - not FDA approved

Doses from Studies

20 mg/kg/day (mice)

PMC Research - NNMT inhibitor obesity study ↗

Duration

4-6 weeks (cycling recommended)

Administration

Subcutaneous injection or oral

Timing & Administration

Best Time to Take

Morning, fasted

Once daily

Food Recommendation

With or without food

Why This Timing?

Morning administration aligns with natural metabolic rhythm and minimizes potential sleep disruption

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Mild headache (initial dosing)
●Nausea
●Increased alertness/jitteriness
●Rare: insomnia
●Rare: elevated blood pressure

References

Research This Peptide Further

PubMed ClinicalTrials.gov FDA.gov

Buy in shop

5-Amino-1MQ from $62/kit

3 verified vendors, ≥99% purity, COAs included.

Compare prices

Frequently Asked Questions

What does 5-Amino-1MQ do?

A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.

How does 5-Amino-1MQ work?

Is 5-Amino-1MQ FDA approved?

No, 5-Amino-1MQ is not currently FDA approved. Current status: Preclinical Research

What are the side effects of 5-Amino-1MQ?

Reported side effects include: Mild headache (initial dosing), Nausea, Increased alertness/jitteriness, Rare: insomnia, Rare: elevated blood pressure. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of 5-Amino-1MQ?

Community-reported common dose: 50-75 mg daily (Once daily, morning). Range: 50-100 mg daily. Administration: Subcutaneous injection or oral. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with 5-Amino-1MQ or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

Orforglipron

FDA

An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.

Weight Loss

CagriSema

Clinical Trials

A combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

How to Use 5-Amino-1MQ 5-Amino-1MQ Alternatives Compare with Similar Browse All Peptides

Want updates on 5-Amino-1MQ research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides